ISSN:
1420-908X
Keywords:
Bradykinin
;
Captopril
;
Bronchoconstriction
;
Tachykinins
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract In anesthetized, mechanically ventilated guinea pigs, infusion of captopril (1 mg/kg/h), an angiotensin converting enzyme inhibitor, significantly enhanced bronchoconstriction induced by intravenous injection of bradykinin (BK; 0.1–30 nmol/kg). Pretreatment of guinea pigs with capsaicin (100 μg/kg) slightly suppressed the bronchoconstriction by BK alone and almost all of the enhancement of BK-induced bronchoconstriction by captopril was suppressed. Intravenous injection of substance P (SP; 0.1–100 nmol/kg), neurokinin A (NKA; 0.1–30 nmol/kg) and neurokinin B (NKB; 0.1–30 nmol/kg) also induced dose-dependent bronchoconstriction but captopril treatment enhanced only the bronchoconstriction induced by SP. BK degradation in bronchoalveolar lavage fluid (BALF) in vitro was significantly suppressed by captopril (p〈0.05). Captopril infusion to guinea pigs significantly increased the levels of BK, SP, and NKA in BALF after BK injection (p〈0.05). FK224, an NK1 and NK2 receptor antagonist and SR 48968, an NK2 receptor antagonist, significantly suppressed the broncoconstriction induced by BK alone (p〈0.01 and p〈0.05, respectively) as well as the enhancement by captopril (p〈0.01). It can be concluded that the enhancement of BK-induced bronchoconstriction by captopril was attributable to inhibition of the degradation of BK itself and thereby enhanced release of NKA and partly of SP from sensory nerves by BK.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02265119
Permalink